Descrizione del progetto
Innovazioni per comprendere e prevenire meglio l’obesità infantile
L’obesità nella tarda adolescenza può esercitare effetti dannosi di lunga durata, contribuendo a peggiorarne l’entità e all’insorgere di patologie quali diabete, malattie cardiovascolari e disabilità. Nel peggiore dei casi, può portare alla morte prematura. Il trattamento dell’obesità in età giovanile, tuttavia, può offrire risultati positivi. Dato l’aumento dei tassi con cui si verifica questa condizione tra i bambini in Europa, è fondamentale dare priorità a strategie di prevenzione e trattamento efficaci. Il progetto OBELISK, finanziato dall’UE, mira a far luce sulle cause dell’obesità e a fornire ai bambini che ne sono affetti capacità di medicina di precisione. Il progetto introdurrà innovazioni nella comprensione dei meccanismi molecolari alla base dell’interazione tra i fattori causali che determinano o prevengono lo sviluppo dell’obesità durante l’infanzia, concependo inoltre una serie di strumenti per la prevenzione precoce. A tal fine, OBELISK collaborerà con svariati interlocutori, quali famiglie, comunità scientifiche e mediche, scuole, comuni e industrie.
Obiettivo
Obesity rates in late teens have increased in Europe from 6% in 1980 to 32%, with long-lasting effects on the prevalence of severe obesity, diabetes and cardiovascular disease, premature death and disability. Efficiently fighting adult obesity is difficult but prevention and treatment of obesity have proven to work better at young ages. OBELISK goal is to cut the roots of the pandemic of obesity in Europe targeting children first. OBELISK is focused on elucidating, Predicting, Preventing obesity and bringing Precision medicine for children with obesity. OBELISK medicine is also Participative (4P), leveraging the potential of social innovation through engagement with families, scientific and medical communities, daycare, schools, municipalities, industries to achieve success.
OBELISK objectives are: 1/ to bring breakthroughs in the molecular mechanisms by which causative factors interact to drive (or prevent) the transition from normal weight to obesity during childhood and to develop and exploit for prevention and treatment early predictive proprietary tools; 2/ to identify at least 3 novel childhood obesity genes with the prospect of identifying additional drug targets; 3/ to demonstrate the utility of targeted approaches to prevent childhood obesity; 4/ to bring breakthroughs in childhood obesity treatment including a real-life clinical study of a promising existing drug (GLP1R agonist) to reverse obesity in people with mutations predisposing to early severe obesity; 5/ to exploit the project results and disseminate best practices to prevent and treat childhood obesity, implementing education programs and translating OBELISK clinical results into guidelines and proposals for policy makers to change obesity care; 6/ to facilitate networking and exchanges with other actions and projects in order to optimize knowledge and joint activities.
OBELISK targeted approach should contribute to decrease by 35% the number of children with obesity becoming adults with obesity.
Campo scientifico
- medical and health scienceshealth sciencespublic healthepidemiologypandemics
- medical and health sciencesclinical medicineendocrinologydiabetes
- medical and health sciencesclinical medicinecardiologycardiovascular diseases
- medical and health scienceshealth sciencespersonalized medicine
- medical and health scienceshealth sciencesnutritionobesity
Parole chiave
Programma(i)
Argomento(i)
Invito a presentare proposte
HORIZON-HLTH-2022-STAYHLTH-01-two-stage
Vedi altri progetti per questo bandoMeccanismo di finanziamento
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinatore
75654 Paris
Francia